Stopping and switching

Switching From Ozempic to Mounjaro: Dose, Blood Sugar, and Safety

Q: Do you restart at the lowest Mounjaro dose even after being on Ozempic 1 mg or 2 mg?

The Mounjaro label gives one starting dose for all adults — 2.5 mg once weekly — with no exception for prior GLP-1 use, and increases in 2.5 mg steps after at least 4 weeks. The conversion chart lines up doses differently but states it does not replace clinical judgment, so the starting dose is a prescriber decision.

Q: Is there an official dose conversion chart between semaglutide and tirzepatide?

The Beth Israel Lahey Health guide, updated 8/2024 and adapted from Whitley (Clinical Diabetes, 2023), lists the weekly doses for each drug — tirzepatide 2.5 through 15 mg, semaglutide 0.25 through 2 mg.

Q: Can both drugs be taken in the same week?

The conversion guide's instruction is to discontinue the current GLP-1 RA agent when converting, which points to sequential use rather than overlap. Both labels describe once-weekly dosing, and the guide lists side effects, glycemic response, and hypoglycemic episodes as things to monitor after a switch from a weekly GLP-1.

Q: Is Mounjaro stronger than Ozempic for A1c and weight?

In SURPASS-2 (40 weeks, background metformin), tirzepatide cut A1c by 2% to 2.3% and weight by 17 to 25 lbs, versus −1.9% and −13 lbs for Ozempic 1 mg. A 2026 model-based analysis — not a trial, with two Novo Nordisk–affiliated authors — estimated a 99.4% probability of weight-loss equivalence between semaglutide 2.4 mg and tirzepatide 10 mg; its only direct head-to-head evidence was in obesity without type 2 diabetes, so equivalence in T2DM remains uncertain.

Q: What happens to blood sugar if there's a gap between prescriptions?

In a small retrospective study of 69 people who stopped a GLP-1 during a shortage, mean HbA1c rose from 7.0% to 8.1% within 3 months and fasting glucose rose from 129 to 156 mg/dL. DPP-4 and SGLT2 substitutes were insufficient in that cohort. The study is small and retrospective, so it shows what can happen, not what always does.

Q: Does insulin or sulfonylurea dosing need to change when switching?

Both labels warn that combining either drug with insulin or an insulin secretagogue, such as a sulfonylurea, raises the risk of hypoglycemia, including severe hypoglycemia, and that reducing the insulin or secretagogue dose may be necessary. That reduction is a prescriber decision, and the conversion guide lists hypoglycemic episodes as something to monitor after a switch.

Q: Will the nausea start over from the beginning on the new drug?

Mounjaro's common reactions include nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal pain, and the label ties its 2.5 mg starting dose and slow escalation to reducing GI reactions. The conversion guide says to consider stepping down a dose when converting if there were prior GI side effects on a GLP-1.

The Mounjaro label gives one starting dose for every adult: 2.5 mg once weekly, with no exception for prior Ozempic use. Conversion charts exist but say they do not replace clinical judgment, and gaps between prescriptions can raise blood sugar fast.

Last checked September 14, 2026·13 sources cited·Ozempic Mounjaro

Two clay injection pens, terracotta and sage, beside a small glucose meter and lancet on a cream surface.

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

The Mounjaro label gives one starting dose for every adult beginning the drug: 2.5 mg injected under the skin once weekly, and it contains no exception or alternate starting dose for people who were previously on Ozempic or any other GLP-1 medicine ^[5]. Doses then go up in 2.5 mg increments after at least 4 weeks on the current dose, if more glycemic control is needed, up to a maximum of 15 mg once weekly in adults ^[5]. A hospital conversion guide lists the two drugs’ doses side by side, but it states plainly that it does not replace clinical judgment, so the actual starting dose is a decision for the prescriber ^[7].

What happens to your blood sugar depends a lot on whether the two prescriptions overlap or leave a gap. In a small study of 69 people with type 2 diabetes who stopped a GLP-1 drug during a shortage, average HbA1c rose from 7.0% to 8.1% within 3 months ^[4]. On the new drug, the side effects to watch for are the same family as Ozempic’s — nausea, diarrhea, vomiting, constipation — plus low blood sugar if you also take insulin or a sulfonylurea ^[1]^[5].

What’s the difference between Ozempic and Mounjaro?

Ozempic is semaglutide, a GLP-1 receptor agonist injection, first approved in the United States in 2017; its prescribing information was revised 05/2026 ^[1]. The label lists three uses: improving glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[1].

Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist injection, first approved in 2022; its prescribing information was revised 08/2026 ^[5]. Its label covers glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes at high risk for these events ^[5]. The cardiovascular indication appears in the label’s Recent Major Changes section dated 08/2026 ^[5].

Both drugs carry the same boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1]^[5].

How common is switching between these drugs?

A retrospective analysis of GLP-1 prescriptions from 2018 to 2025 in Poland’s largest private healthcare network looked at 42,423 patients with more than one prescription and found that 29.7% switched agents at least once, and 14.3% switched two or more times ^[2]. Within that group, 12,620 patients contributed 27,095 prescription-to-prescription transitions ^[2]. The analysis found accelerated tirzepatide uptake after it entered the market ^[2]. The authors note that reasons for switching were not measured and the associations should be treated as hypothesis-generating ^[2].

A published rationale for switching comes from a small retrospective case series: switching can be considered for people with type 2 diabetes who need further A1C and weight reduction despite being on a GLP-1 receptor agonist ^[3].

What dose of Mounjaro does the label say to start at?

The recommended starting dosage of Mounjaro is 2.5 mg injected subcutaneously once weekly ^[5]. If additional glycemic control is needed, the dose increases in 2.5 mg increments after at least 4 weeks on the current dose ^[5]. The maximum is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years and older ^[5]. The label states that following the starting dose and escalation schedule is a way to reduce the risk of gastrointestinal adverse reactions ^[5].

For comparison, Ozempic starts at 0.25 mg once weekly, moves to 0.5 mg after 4 weeks, and then to 1 mg and 2 mg, each after at least 4 weeks on the prior dose if more glycemic control is needed ^[1].

Mounjaro comes in single-dose pens and vials at 2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL, and in multi-dose vials and KwikPens that each hold four doses ^[5].

Is there an Ozempic to Mounjaro dose conversion chart?

A conversion guide from Beth Israel Lahey Health, updated 8/2024, covers only brands indicated for type 2 diabetes and is adapted from a 2023 paper by Whitley in Clinical Diabetes ^[7]. It lists the weekly doses for each agent side by side in one comparative chart ^[7]:

Medication	Route and interval	Doses listed in the guide
Tirzepatide (Mounjaro)	Injection once weekly	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Semaglutide (Ozempic)	Injection once weekly	0.25 mg, 0.5 mg, 1 mg, 2 mg

The guide carries two important caveats: the chart is based on relative effect on A1c and does not address the potential for side effects, and it does not replace clinical judgment ^[7]. It also gives workflow rules: if the switch is prompted by side effects, start with the lowest available dose, titrate more slowly, and consider a lower maintenance dose; if prompted by other reasons, start with the equivalent dose and consider a lower one if side effects occurred during titration ^[7]. It warns not to switch from a submaximal dose of one agent to the maximum dose of another, and to consider stepping down a dose if the patient had GI side effects on a GLP-1 in the past ^[7]. The guide treats the drugs as sequential: discontinue the current GLP-1 agent when converting ^[7].

Is Mounjaro stronger than Ozempic for A1c and weight?

In SURPASS-2, a 40-week trial summarized in the conversion guide, tirzepatide at 5, 10, and 15 mg was compared with semaglutide 1 mg in people with type 2 diabetes on background metformin ^[7]:

Result at 40 weeks	Mounjaro 5 mg	Mounjaro 10 mg	Mounjaro 15 mg	Ozempic 1 mg
A1c reduction	−2%	−2.2%	−2.3%	−1.9%
Weight loss	−17 lbs	−21 lbs	−25 lbs	−13 lbs
Discontinuation due to GI adverse events	2.8%	4.3%	4.3%	3.2%

A separate model-based analysis published in Diabetes Therapy in 2026 pooled arm-level data from phase III trials of both drugs in type 2 diabetes — 48 treatment arms and 16,524 participants — and estimated probabilities of clinical equivalence for weight loss using a margin of ±2 percentage points ^[8]. It found a 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg are clinically equivalent for weight change, and 94.8% for semaglutide 7.2 mg versus tirzepatide 15 mg ^[8]. Lower semaglutide doses were not equivalent to higher tirzepatide doses, and the authors concluded equivalence was driven by dose rather than drug identity ^[8]. Both drugs showed nonlinear dose–response, with diminishing incremental effect at higher doses ^[8].

One thing to note: the modeled semaglutide doses — 2.4 mg and 7.2 mg weekly — are above the Ozempic label’s maximum of 2 mg, so they do not correspond to any Ozempic prescription strength ^[1]^[8].

Three cautions on that analysis: it is a model, not a trial; it has two Novo Nordisk–affiliated authors; and the analysis notes that its only direct head-to-head evidence, SURMOUNT-5, came from people with obesity but without type 2 diabetes, at maximum tolerated doses rather than the full range of clinically relevant doses, so dose equivalence in type 2 diabetes remains uncertain ^[8]. The equivalence figures are not a switching rule.

What actually happened to people who switched?

A retrospective case series published in Hospital Pharmacy in 2024 followed 10 patients with type 2 diabetes who switched from a GLP-1 receptor agonist to tirzepatide under a protocol ^[3]. Mean A1C fell 0.7 ± 0.9% from baseline at 3 months (8 patients measured) and 1.4 ± 0.7% at 6 months (4 patients measured) ^[3]. Of those measured, 25% reached their goal A1C at 3 months and 50% at 6 months ^[3]. Mean weight fell 3.6 ± 2.3 kg at 3 months and 6 ± 3.4 kg at 6 months ^[3]. For the endpoint of losing at least 10% of baseline weight, no patient reached it at 3 months, and 33.3% (1 of 3 patients with that measurement) did at 6 months ^[3]. Few adverse events were reported after switching ^[3].

This is a small, retrospective series with only 10 patients and incomplete follow-up, so it is best read as hypothesis-generating, not as evidence of what any one person should expect ^[3]. The authors themselves note there is a lack of data on how to switch between the GLP-1 RA and GIP/GLP-1 RA classes ^[3].

How long should you wait between the last Ozempic shot and the first Mounjaro shot?

The labels and the conversion guide give no washout instruction between the two drugs. The conversion guide treats the agents as sequential — discontinue the current GLP-1 RA when converting — and both drugs are once-weekly injections ^[1]^[5]^[7]. The timing of the first Mounjaro dose is part of the switch plan a prescriber sets.

What the labels do give are rules for missed doses and schedule changes on each drug. For Ozempic, a missed dose should be administered within 5 days of the missed dose ^[1]. For Mounjaro, a missed dose should be given as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip it and take the next dose on the regularly scheduled day, then resume the weekly schedule ^[5]. The day of weekly Mounjaro administration can be changed if necessary, as long as at least 3 days (72 hours) elapse between the two doses ^[5]. Both drugs are given once weekly at any time of day, with or without meals, injected into the abdomen, thigh, or upper arm — for Mounjaro, the upper arm is injected by another person — with rotation of injection sites ^[1]^[5].

What happens to blood sugar if there’s a gap between prescriptions?

Gaps matter. In a study of 69 people with type 2 diabetes who stopped dulaglutide during a GLP-1 shortage, mean HbA1c rose from 7.0% ± 0.9% to 8.1% ± 1.4% (P<0.001) within 3 months, and fasting glucose rose from 129 ± 31 to 156 ± 50 mg/dL (P<0.001) ^[4]. Switching to DPP-4 inhibitors or SGLT2 inhibitors was an insufficient substitute in that cohort ^[4]. Like the case series above, this is a small, retrospective look at one shortage situation, so it suggests what can happen rather than what always does ^[4].

The conversion guide includes restart rules for a lapse in therapy. For someone whose last tirzepatide dose was 5 mg once weekly or higher: if fewer than 2 doses were missed, resume the same dose if it was adequately tolerated; if 3 or more doses were missed, restart at 5 mg once weekly, or consider 2.5 mg if there is concern about GI side effects ^[7]. For someone whose last subcutaneous semaglutide dose was 1 mg once weekly: if 2 or fewer doses were missed, restart at 1 mg; if 3–4 were missed, restart at 0.5 mg; if 5 or more were missed, restart at 0.25 mg ^[7].

Do insulin or sulfonylurea doses need to change when switching?

Both labels carry the same warning: taking the drug with an insulin secretagogue (such as a sulfonylurea) or with insulin can increase the risk of hypoglycemia, including severe hypoglycemia, and reducing the dose of the secretagogue or insulin may be necessary ^[1]^[5]. Whether and how much to reduce is a prescriber’s decision — the labels frame it that way, and the conversion guide lists hypoglycemic episodes as something to monitor after switching from a weekly GLP-1 ^[5]^[7].

Two other interaction points are worth knowing. Both drugs delay gastric emptying and may affect the absorption of other oral medicines; the Ozempic label says to use with caution ^[1]^[5]. The Mounjaro label advises females using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase ^[5]. The Ozempic label says to discontinue Ozempic in women at least 2 months before a planned pregnancy, because of semaglutide’s long washout period ^[1].

What side effects should you expect on the new drug?

The common side effects overlap heavily. For Mounjaro, reactions reported in at least 5% of patients are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain ^[5]. For Ozempic, they are nausea, vomiting, diarrhea, abdominal pain, and constipation ^[1]. The Mounjaro label ties its starting dose and escalation schedule directly to reducing the risk of these GI reactions ^[5].

The serious warnings are also nearly identical on both labels: acute pancreatitis (discontinue if suspected), severe GI reactions (not recommended in severe gastroparesis), acute kidney injury from volume depletion, serious hypersensitivity including anaphylaxis and angioedema, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation — patients should tell healthcare providers about planned surgeries or procedures ^[1]^[5]. Both labels say never to share a pen between patients, even if the needle is changed ^[1]^[5].

One monitoring item: the Ozempic label says patients with a history of diabetic retinopathy should be monitored, and the Mounjaro label says to monitor patients with a history of diabetic retinopathy for progression — a warning added 08/2026 ^[1]^[5].

What should you bring to the appointment?

The information a prescriber needs for a switch maps to the inputs in the conversion guide: the current agent and dose, whether GI side effects occurred before or during titration, the glycemic response so far, and any hypoglycemic episodes ^[7]. The date of the last injection matters too, because the restart dose after a lapse depends on how many doses were missed ^[7].

Questions worth asking, drawn from the labels and guide: whether the insulin or sulfonylurea dose should be reduced at the same time ^[1]^[5]; what to monitor in the first weeks after the switch — side effects, glycemic response, hypoglycemic episodes ^[7]; and whether the specific Mounjaro dose strength is in stock, since the conversion guide points to the FDA Drug Shortages website for up-to-date dose availability ^[7].

Sources

Frequently asked questions

Do you restart at the lowest Mounjaro dose even after being on Ozempic 1 mg or 2 mg?

The Mounjaro label gives one starting dose for all adults — 2.5 mg once weekly — with no exception for prior GLP-1 use, and increases in 2.5 mg steps after at least 4 weeks. The conversion chart lines up doses differently but states it does not replace clinical judgment, so the starting dose is a prescriber decision.

Is there an official dose conversion chart between semaglutide and tirzepatide?

The Beth Israel Lahey Health guide, updated 8/2024 and adapted from Whitley (Clinical Diabetes, 2023), lists the weekly doses for each drug — tirzepatide 2.5 through 15 mg, semaglutide 0.25 through 2 mg.

How long should you wait after the last Ozempic shot before the first Mounjaro shot?

The labels and the conversion guide give no washout instruction. The guide treats the drugs as sequential: discontinue the current GLP-1 RA when converting. Both are once-weekly injections, and the timing of the first Mounjaro dose is part of the plan a prescriber sets.

Can both drugs be taken in the same week?

The conversion guide's instruction is to discontinue the current GLP-1 RA agent when converting, which points to sequential use rather than overlap. Both labels describe once-weekly dosing, and the guide lists side effects, glycemic response, and hypoglycemic episodes as things to monitor after a switch from a weekly GLP-1.

Is Mounjaro stronger than Ozempic for A1c and weight?

In SURPASS-2 (40 weeks, background metformin), tirzepatide cut A1c by 2% to 2.3% and weight by 17 to 25 lbs, versus −1.9% and −13 lbs for Ozempic 1 mg. A 2026 model-based analysis — not a trial, with two Novo Nordisk–affiliated authors — estimated a 99.4% probability of weight-loss equivalence between semaglutide 2.4 mg and tirzepatide 10 mg; its only direct head-to-head evidence was in obesity without type 2 diabetes, so equivalence in T2DM remains uncertain.

What happens to blood sugar if there's a gap between prescriptions?

In a small retrospective study of 69 people who stopped a GLP-1 during a shortage, mean HbA1c rose from 7.0% to 8.1% within 3 months and fasting glucose rose from 129 to 156 mg/dL. DPP-4 and SGLT2 substitutes were insufficient in that cohort. The study is small and retrospective, so it shows what can happen, not what always does.

Does insulin or sulfonylurea dosing need to change when switching?

Both labels warn that combining either drug with insulin or an insulin secretagogue, such as a sulfonylurea, raises the risk of hypoglycemia, including severe hypoglycemia, and that reducing the insulin or secretagogue dose may be necessary. That reduction is a prescriber decision, and the conversion guide lists hypoglycemic episodes as something to monitor after a switch.

Will the nausea start over from the beginning on the new drug?

Mounjaro's common reactions include nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal pain, and the label ties its 2.5 mg starting dose and slow escalation to reducing GI reactions. The conversion guide says to consider stepping down a dose when converting if there were prior GI side effects on a GLP-1.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.